Sintx Technologies, Inc. (SINT) Fair Value 2026

SINT · Medical Devices ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

5.7 /10

32 fundamental signals · 2 models active

Value Trap Risk

LOW (35/100)

Quick Summary — As of 2026-08-27, Sintx Technologies, Inc. (SINT) trades at $1.53, versus a $2.99 median fair value across its 2 active models — 95.3% above the current price. QOC: 5.7/10. Value Trap Risk: 35/100 (LOW). 2/13 models active.

Key Facts

Ticker
SINT
Price
$1.53
Quality Score
5.7/10
Value Trap Risk
35/100
Models Active
2/13
Last Updated
Strength: Dynamic NAV suggests +206.8% upside with 52% confidence
Risk: Limited model coverage (2/13) may reduce confidence

Is Sintx Technologies, Inc. (SINT) Undervalued or Overvalued in 2026?

According to CirclFi’s 2-model valuation engine, Sintx Technologies, Inc. (SINT) appears undervalued as of : the median of 2 independent fair value estimates is $2.99, 95.3% above the current price of $1.53. Estimates range from $1.28 to $4.69. SINT scores 5.7/10 on fundamental quality and 35/100 on value-trap risk.

For context, the median US equity CirclFi rates trades at an implied -23.7% versus its own 13-model consensus, across 3,801 rated companies as of 2026-08-27. SINT’s +95.3% gap is wider than that market norm, and the Medical Devices sector median is -43.5%. Full market index →

This verdict compares price to intrinsic value only — it is not a buy or sell rating. For the decision case (bull vs bear arguments, risk factors, peers), read Should You Buy Sintx Technologies, Inc. Stock in 2026? →

What Fair Value Does Each Model Give SINT?

2 Intrinsic Value Models vs. Current Price ($1.53)

Core Models (Unlocked)
Model Fair Value Upside
Asset-Based · High Conviction
 $4.69 +206.8%
Option-Based · Medium Conviction
 $1.28 -16.3%

All Models Active

All 2 models are displayed above.

What Is Sintx Technologies, Inc. (SINT) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Sintx Technologies, Inc.'s intrinsic value is estimated at a median $2.99, showing conflicting signals at the current price of $1.53. While the median implied return is +95.3%, model disagreement is elevated with a gap of +223.1% between the most bullish and bearish estimates. The most optimistic model, Dynamic NAV, places fair value at $4.69 (+206.8%), while PWERM — the most conservative — estimates $1.28 (-16.3%). This +223.1% gap reflects genuine analytical uncertainty about Sintx Technologies, Inc.'s intrinsic worth.

What Do the Models Say About SINT?

2 of 13 models are currently active for SINT. Of these, 1 model suggests upside while 1 model suggests overvaluation. Taken together, their median fair value for SINT is $2.99 — the figure CirclFi publishes as this stock's fair value. See which stocks rank higher →

How Does SINT Rank in Medical Devices?

Among 157 Medical Devices stocks, SINT ranks #103 by Quality of Company score. CirclFi's QOC score of 5.7/10 evaluates 32 fundamental signals. A score of 5.7 reflects mixed fundamentals.

See all Most Undervalued Medical Devices Stocks →

Sintx Technologies, Inc.'s positioning within the Medical Devices segment means that FDA approval probability plays an outsized role in fundamental analysis. The sector's unique characteristics — including late-stage pipeline catalysts — shape both the opportunity set and risk profile.

Is SINT a Value Trap?

CirclFi's Value Trap algorithm assigns SINT a score of 35/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

2 of 13 models are active for Sintx Technologies, Inc.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Quality of Company (QOC) framework, Sintx Technologies, Inc. earns a quality score of 5.7/10. This respectable rating reflects the company's standing across 32 fundamental signals spanning profitability, growth consistency, balance sheet strength, and capital allocation efficiency.

The gap between the most bullish and bearish model spans +223.1% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every SINT valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across SINT's 2 active models, average confidence is 42%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Sintx Technologies, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Medical Devices Stocks Should You Also Analyze?

11 related Medical Devices stocks with 13-model coverage

BMRABiomerica, Inc.QOC 5.7QTIQT Imaging Holdings, Inc.QOC 5.6TLSITriSalus Life Sciences, Inc.QOC 5.7NNOXNano-X Imaging Ltd.QOC 5.6VNRXVolitionRx LimitedQOC 5.7LFWDLifeward Ltd.QOC 5.6AMIXAutonomix Medical, Inc.QOC 4.2BVSBioventus Inc.QOC 8.2NSYSNortech Systems IncorporatedQOC 6.6IRMDIRADIMED CORPORATIONQOC 9.8PODDInsulet CorporationQOC 9.6

Read investment analysis: BMRA · QTI · TLSI · NNOX · VNRX · LFWD · AMIX · BVS · NSYS · IRMD · PODD

Which Other Stocks Have a Similar Quality Score to SINT?

7 companies across all industries closest to SINT’s Quality of Company score of 5.7/10.

RCONRecon Technology, Ltd.QOC 5.7AAPGAscentage Pharma Group InternatQOC 5.7TVGrupo Televisa, S.A.B.QOC 5.7MFBIMonroe Federal Bancorp, Inc.QOC 5.7SVRESaverOne 2014 Ltd.QOC 5.7QURTQuarta-Rad, Inc.QOC 5.7NVDANVIDIA CorporationQOC 10.0

Read investment analysis: RCON · AAPG · TV · MFBI · SVRE · QURT · NVDA

Where Does SINT Sit in CirclFi's Medical Devices Rankings?

SINT is ranked against every other Medical Devices stock CirclFi covers in each of these screens.

See all Medical Devices stocks ranked →

What Else Do Investors Ask About Sintx Technologies, Inc.’s Valuation?

What is Sintx Technologies, Inc.'s intrinsic value in 2026?

CirclFi puts Sintx Technologies, Inc. (SINT)'s intrinsic value at $2.99 — the median of 2 independent model estimates as of 2026-08-27, ranging from $1.28 to $4.69. The Quality of Company score is 5.7/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is SINT overvalued or undervalued right now?

At $1.53, 1 of 2 active models suggest SINT may be undervalued, while 1 indicate potential overvaluation. The median of all 2 fair value estimates is $2.99, 95.3% above the current price of $1.53 — a consensus view that SINT is undervalued. The assessment depends on which methodology best fits Sintx Technologies, Inc.'s business model in Medical Devices.

What does a Quality of Company score of 5.7 mean for SINT?

Sintx Technologies, Inc.'s QOC of 5.7/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores between 5-7 reflect moderate fundamentals with areas for improvement.

How many valuation models does CirclFi run on SINT?

CirclFi analyzes SINT with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 2 of 13 are active for this stock. Read the full methodology →

Is SINT a value trap in 2026?

Sintx Technologies, Inc.'s Value Trap score is 35/100 (LOW). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap. Browse stocks by value-trap risk →

Cite this analysis — “According to CirclFi’s 2-model valuation engine, Sintx Technologies, Inc. (SINT) has a median fair value of $2.99 — 95.3% above the current price of $1.53 — as of 2026-08-27.” Source: circlfi.com/stock/SINT/ · Methodology
Primary sources for this SINT valuation
  • Financial statements: Sintx Technologies, Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0001269026) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for SINT as of ; valuations recomputed .